Quarterly report pursuant to Section 13 or 15(d)

ORGANIZATION AND BUSINESS (Details)

v3.21.2
ORGANIZATION AND BUSINESS (Details)
 3 Months Ended 6 Months Ended
Jul. 31, 2021
USD ($)
May 28, 2021
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Jun. 30, 2020
Facility
Mar. 31, 2020
USD ($)
Jun. 30, 2021
USD ($)
Facility
Product
Aug. 11, 2021
USD ($)
Dec. 31, 2020
USD ($)
Organization and Business [Abstract]                  
Number of Plasma Collection Facilities Under Development | Facility         8   8    
Number of FDA-Licensed Plasma Collection Facilities | Facility         2   2    
Number of FDA approved product | Product             3    
Working capital     $ 153,200,000       $ 153,200,000    
Cash and cash equivalents     42,400,000       42,400,000    
Cumulative losses     (377,750,347)       $ (377,750,347)   $ (340,465,103)
Common stock issuable under agreement     $ 17,189,560 $ 41,912,515   $ 88,704,039      
Minimum [Member]                  
Organization and Business [Abstract]                  
Production cycle from procurement of raw materials to release of finished product             7 months    
Maximum [Member]                  
Organization and Business [Abstract]                  
Production cycle from procurement of raw materials to release of finished product             12 months    
Jefferies [Member] | 2020 Sale Agreement [Member]                  
Organization and Business [Abstract]                  
Proceeds from sales of common stock             $ 59,100,000    
Jefferies [Member] | 2020 Sale Agreement [Member] | Subsequent Event [Member]                  
Organization and Business [Abstract]                  
Proceeds from sales of common stock $ 1,500,000                
Jefferies [Member] | 2021 Sale Agreement [Member] | Subsequent Event [Member]                  
Organization and Business [Abstract]                  
Sales of common stock               $ 0  
Jefferies [Member] | 2021 Sale Agreement [Member] | Maximum [Member]                  
Organization and Business [Abstract]                  
Common stock issuable under agreement   $ 50,000,000